➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Merck
Johnson and Johnson
Boehringer Ingelheim
Dow

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for NB-001

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for NB-001?

NB-001 is an investigational drug.

There have been 5 clinical trials for NB-001. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2011.

The most common disease conditions in clinical trials are Herpes Labialis, Glaucoma, and Herpes Simplex. The leading clinical trial sponsors are NanoBio Corporation, Danube Pharmaceuticals, Inc., and [disabled in preview].

There is one US patent protecting this investigational drug and ten international patents.

Recent Clinical Trials for NB-001
TitleSponsorPhase
NB-001 Treatment of Recurrent Herpes LabialisNanoBio CorporationPhase 3
A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes LabialisNanoBio CorporationPhase 3
A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)NanoBio CorporationPhase 3

See all NB-001 clinical trials

Clinical Trial Summary for NB-001

Top disease conditions for NB-001
Top clinical trial sponsors for NB-001

See all NB-001 clinical trials

International Patents for NB-001

Drugname Country Document Number Estimated Expiration Related US Patent
NB-001 Australia 2017204462 2036-08-01   Start Trial
NB-001 Canada 2973033 2036-08-01   Start Trial
NB-001 China 107674078 2036-08-01   Start Trial
NB-001 European Patent Office 3279200 2036-08-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Merck
Johnson and Johnson
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.